ANI Pharmaceuticals, Inc. (ANIP)
| Market Cap | 1.51B -25.9% |
| Revenue (ttm) | 1.04B +25.9% |
| Net Income | 108.53M +188.0% |
| EPS | 5.00 +198.7% |
| Shares Out | 21.18M |
| PE Ratio | 14.21 |
| Forward PE | 7.53 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,011,689 |
| Open | 70.87 |
| Previous Close | 71.25 |
| Day's Range | 70.38 - 72.24 |
| 52-Week Range | 67.14 - 90.73 |
| Beta | 0.47 |
| Analysts | Buy |
| Price Target | 105.22 (+48.01%) |
| Earnings Date | Nov 5, 2026 |
About ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, gr... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for ANIP stock is "Buy." The 12-month stock price target is $105.22, which is an increase of 48.01% from the latest price.
News
ANI Pharmaceuticals Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
EMCITATE adds a rare-disease growth asset with $300M+ peak-sales potential, while Cortrophin demand continued to rise amid pharmacy conversion constraints. FY2026 revenue guidance is $480M–$500M, and post-deal net leverage is expected at ~2.7x.
ANI Pharmaceuticals price target raised to $121 from $119 at Guggenheim
Guggenheim analyst Vamil Divan raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $121 from $119 and keeps a Buy rating on the shares.
ANI Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 revenue grew 28% and Adjusted EBITDA 40%, while pharmacy bottlenecks lowered Cortrophin guidance. The Egetis offer adds EMCITATE, with closing expected in late 2026 or early 2027 and first-year dilution anticipated.
ANI Pharmaceuticals Earnings release: Q3 2026
ANI Pharmaceuticals released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
ANI Pharmaceuticals Quarterly report: Q3 2026
ANI Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 5, 2026.
ANI Pharmaceuticals Slides: Q3 2026
ANI Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
ANI Pharmaceuticals reports Q3 adjusted EPS $2.70, consensus $2.18
Reports Q3 revenue $290.8M, consensus $280.2M. “In the third quarter, ANI delivered strong financial results, while advancing our transformation into a leading Rare Disease company,” said Nikhil Lalwa...
ANI Pharmaceuticals raises FY26 adjusted EPS to $9.37-$9.71 from $9.19-$9.69
FY26 consensus $9.26. Narrows FY26 revenue to $1.085B-$1.125B from $1.08B-$1.14B, consensus $1.1B.
ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results
PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the third quarter ended S...
REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ) (“Ege...
ANI announces offer to acquire Egetis Therapeutics for SEK 11.25 per share
ANI Pharmaceuticals (ANIP) announced a recommended public offer to acquire Egetis Therapeutics. Egetis is a commercial-stage pharmaceutical company focused on developing and delivering innovative ther...
ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ) (“Ege...
ANI Pharmaceuticals to Present at Upcoming November Investor Conferences
PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with ...
ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET
PRINCETON, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its third quarter 2026 financial results ...
ANI Pharmaceuticals launches Duloxetine Delayed-Release Capsules
ANI Pharmaceuticals (ANIP) announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. ANI’s Duloxetine Delayed-Release Capsules are the generic version of the reference listed drug,...
ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules
PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. ANI...
ANI Pharmaceuticals reports ‘positive’ results from Phase 4 Synchronicity trial
ANI Pharmaceuticals (ANIP) announced that both 6-month and 24-month data from SYNCHRONICITY, its Phase 4, open-label, single-arm clinical trial of Fluocinolone Acetonide Intravitreal Implant in patien...
ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting
Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026
ANI receives FDA approval for its ANDA for Everolimus Tablets
ANI Pharmaceuticals (ANIP) announced that it received final approval from the FDA for its Abbreviated New Drug Application, or ANDA, for Everolimus Tablets for Oral Suspension 2mg, 3mg and 5mg.
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S. Food and Drug Administra...
ANI Pharmaceuticals initiated with a Perform at Oppenheimer
Oppenheimer analyst Les Sulewski initiated coverage of ANI Pharmaceuticals (ANIP) with a Perform rating and $85 price target The firm views the company’s Cortrophin Gel as an attractive, durable rare…
ANI Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The company is rapidly expanding its rare disease portfolio, with Cortrophin Gel and ILUVIEN driving growth and a strong generics business providing cash flow. Revised 2026 guidance reflects early-year headwinds, but robust sales force expansion and clinical initiatives support long-term growth.
ANI Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company has rapidly transformed into a Rare Disease leader, with Cortrophin Gel and generics driving strong revenue and EBITDA growth. Expansion into new specialties and robust capital allocation support continued growth, while new data for ILUVIEN and a durable Rare Disease portfolio underpin a positive long-term outlook.
ANI Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
The company is rapidly transforming into a rare disease leader, driven by strong growth in Cortrophin and ILUVIEN, robust generics performance, and strategic expansion into new indications and markets. Record financial results and a solid cash position support ongoing organic and inorganic growth.
ANI Pharmaceuticals initiated with an Outperform at Leerink
Leerink analyst Daniel Clark initiated coverage of ANI Pharmaceuticals (ANIP) with an Outperform rating and $104 price target The firm believes Cortophin Gel’s opportunity in acute gouty arthritis fla...